13F Holdings
中文EN

NVAX NOVAVAX INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1000694 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-61.3%
TTM net income YoY-122.5%
TTM EPS YoY-125.9%
Revenue 3-yr CAGR-26.8%
Net income 3-yr CAGR—

Margins

Gross margin78.0%
Operating margin-21.2%
Net margin-18.6%
FCF margin-59.2%
EBITDA margin-17.7%

Returns

ROE—
ROA-7.4%
ROIC (approx.)—
Asset turnover0.40x

Leverage & solvency

Liabilities / assets124.4%
Debt / equity—
Current ratio2.15x
Interest coverage-4.01x

Cash quality & payout

Operating cash flow / net income3.11x
Accruals ratio15.7%
Payout ratio—
Capex / revenue1.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$1.12B$682.16M$983.71M$1.98B$1.15B
Cost of revenue$73.04M$202.74M$343.77M$902.64M$0
Gross profit$1.05B$479.42M$639.94M$1.08B$1.15B
R&D expense$342.32M$391.17M$737.50M$1.24B$2.53B
SG&A expense$157.48M$337.19M$468.95M$488.69M$298.36M
Operating income$452.80M-$248.93M-$566.51M-$644.74M-$1.69B
Interest expense$22.55M$20.07M$14.42M$19.88M$21.13M
Pretax income$442.17M-$176.62M-$543.03M-$653.65M-$1.71B
Income tax$1.86M$10.88M$2.03M$4.29M$29.21M
Net income$440.30M-$187.50M-$545.06M-$657.94M-$1.74B
EBITDA$480.80M-$200.93M-$525.51M-$615.74M-$1.67B
EPS (basic)2.72-1.23-5.41-8.42-23.44
EPS (diluted)2.58-1.23-5.41-8.42-23.44
Weighted avg. shares (diluted)173.10M152.19M100.77M78.18M74.40M
Balance sheet
Cash & equivalents$240.63M$545.29M$568.50M$1.35B$1.53B
Short-term investments$494.45M$392.89M$0—$0
Receivables————$454.99M
Inventory$11.54M$8.75M$41.70M$36.68M$8.87M
Current assets$978.28M$1.13B$1.14B$1.70B$2.16B
PP&E, net$44.80M$138.41M$305.77M$294.25M$225.74M
Goodwill$113.46M$107.48M$127.45M$126.33M$131.48M
Intangibles————$4.77M
Total assets$1.18B$1.56B$1.80B$2.26B$2.58B
Current liabilities$459.95M$1.15B$1.64B$2.46B$2.39B
Long-term debt$244.21M————
Total debt$244.21M————
Total liabilities$1.30B$2.18B$2.51B$2.89B$2.93B
Shareholders' equity-$127.75M-$623.84M-$716.93M-$634.08M-$351.67M
Net debt$3.58M————
Shares outstanding162.58M160.42M139.51M86.04M75.84M
Cash flow statement
Operating cash flow-$244.63M-$87.26M-$713.97M-$415.94M$322.95M
Capital expenditure$5.56M$13.06M$53.77M$89.06M$54.50M
Free cash flow-$250.19M-$100.32M-$767.74M-$504.99M$268.44M
Investing cash flow-$78.27M-$204.04M-$58.81M-$92.98M$100.15M
Financing cash flow$27.74M$260.58M$4.47M$324.99M$461.71M
Depreciation & amortization$28.00M$48.00M$41.00M$29.00M$13.00M
Stock-based compensation$36.02M$48.15M$85.36M$130.30M$183.63M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.